SELLAS Life Sciences Group, Inc.
SLS
$6.29
$1.0720.40%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -32.28% | -3.37% | 23.29% | -36.97% | 16.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.76% | -3.36% | -9.81% | -37.14% | -1.94% |
| Operating Income | 10.76% | 3.36% | 9.81% | 37.14% | 1.94% |
| Income Before Tax | -13.67% | 4.46% | 11.63% | 39.23% | 17.20% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.67% | 4.46% | 11.63% | 39.23% | 17.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.67% | 4.46% | 11.63% | 39.23% | 17.20% |
| EBIT | 10.76% | 3.36% | 9.81% | 37.14% | 1.94% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 40.50% | 39.87% | 48.30% | 68.99% | 65.51% |
| Normalized Basic EPS | 56.19% | 39.78% | 48.27% | 68.97% | 59.90% |
| EPS Diluted | 40.50% | 39.87% | 46.15% | 68.99% | 65.51% |
| Normalized Diluted EPS | 56.19% | 39.78% | 48.27% | 68.97% | 59.90% |
| Average Basic Shares Outstanding | 90.93% | 58.81% | 71.02% | 95.84% | 140.18% |
| Average Diluted Shares Outstanding | 90.93% | 58.81% | 71.02% | 95.84% | 140.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |